Table 2.
XPO5 promoter methylation status among breast cancer cases and controls
| MI | All | Premenopausa | Postmenopausal | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Tertile | Controls (%) | Cases (%) | OR* (95% CI) | Controls (%) | Cases (%) | OR* (95% CI) | Controls (%) | Cases (%) | OR*(95% CI) |
| Low | 27 (33.3) | 36 (46.1) | Ref. | 11 (45.8) | 9(52.9) | Ref. | 16 (28.1) | 27 (44.3) | Ref. |
| Mid | 27 (33.3) | 25 (32.1) | 0.60 (0.27-1.33) | 5 (20.9) | 6 (35.3) | 1.16 (0.23-5.94) | 22 (38.6) | 19 (31.1) | 0.47 (0.18-1.20) |
| High | 27 (33.3) 17 (21.8) 0.34 (0.15-0.81) 8 (33.3) | 2 (11.8) | 0.38 (0.05-3.13) | 19 (33.3) | 15 (24.6) | 0.32 (0.11-0.88) | |||
| Mid+High | 54 (66.6) | 42 | 0.47 (0.24-0.94) | 13 (54.2) | 8 (47.1) | 0.77 (0.19-3.19) | 41 (72.9) | 34 (55.7) | 0.40 (0.17-0.91) |
| P for Trend | 0.015 | 0.469 | 0.024 | ||||||
*
Adjusted for age, race, family history of breast cancer, BMI, menopausal status (all only), parity, and study site